FDA.reportPublic FDA data

Badiance Cream

Manufacturer
Yiwu Jingmo trade Co., LTD
Effective date
2024-11-17
Label type
HUMAN OTC DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-06-01 00:37:45

Label at a glance#

ProductBadiance Cream
Active ingredientCOPPER TRIPEPTIDE-1
Label structure11 sections

Label contents#

Full prescribing information#

COMPONENTS

Copper Tripeptide-1：5%

OTC - PURPOSE SECTION

skin whitening

INDICATIONS & USAGE SECTION

Prohibit ingestion by mouth.

Do not put into eyes or ears.

No contact with wounds.

DOSAGE & ADMINISTRATION SECTION

For external use only

OTC - DO NOT USE SECTION

Skin irritation occurs, wash with water, discontinue use

If symptoms do not improve, seek medical attention immediately

OTC - WHEN USING SECTION

Skin irritation occurs, wash with water, discontinue use

If symptoms do not improve, seek medical attention immediately。

Allow 5 minutes for the product to take effect

OTC - STOP USE SECTION

Wound breaks

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

If sxralowed, get medical help or contact a Poison Conirol Cenler ngiht away

INACTIVE INGREDIENT SECTION

Aqua，Glycerin，Propylene Glycol，Palmitoyl Tripeptide-1，Palmitoyl Tetrapeptide-7，Palmitoyl Pentapeptide-4，，Pantothenic Acid

WARNINGS SECTION

Apply to skin until absorbed

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

11

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
84864-333-012026-01-29C16284748780-149896155-a6eb-586f-e063-e6dba90add9027189ad9-080f-0515-e063-6394a90ae32d
84864-333-022026-01-29C16284748780-149896155-a6eb-586f-e063-e6dba90add9027189ad9-080f-0515-e063-6394a90ae32d
84864-333-032026-01-29C16284748780-149896155-a6eb-586f-e063-e6dba90add9027189ad9-080f-0515-e063-6394a90ae32d
84864-333-042026-01-29C16284748780-149896155-a6eb-586f-e063-e6dba90add9027189ad9-080f-0515-e063-6394a90ae32d
84864-333-052026-01-29C16284748780-149896155-a6eb-586f-e063-e6dba90add9027189ad9-080f-0515-e063-6394a90ae32d

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
84864-333-01Badiance Cream5 g in 1 BOXCREAM51
84864-333-02Badiance Cream15 g in 1 BOXCREAM151
84864-333-03Badiance Cream30 g in 1 BOXCREAM301
84864-333-04Badiance Cream50 g in 1 BOXCREAM501
84864-333-05Badiance Cream60 g in 1 BOXCREAM601

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
84864-333BADIANCE CREAM CREAM [YIWU JINGMO TRADE CO., LTD]15 package rows20241120_27189ad9-080f-0515-e063-6394a90ae32d.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
84864-33384864-333-01, 84864-333-02, 84864-333-03, 84864-333-04, 84864-333-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Name, UNII, Kind table
NameUNIIKind
PROPYLENE GLYCOL6DC9Q167V3IACT
AQUA059QF0KO0RIACT
GLYCERINPDC6A3C0OXIACT
PALMITOYL TETRAPEPTIDE-7Q41S464P1RIACT
COPPER TRIPEPTIDE-16BJQ43T1I9ACTIB
PALMITOYL PENTAPEPTIDE-4KK181SM5JGIACT
PALMITOYL TRIPEPTIDE-1RV743D216MIACT
PANTOTHENIC ACID19F5HK2737IACT

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
27189ad9-0810-0515-e063-6394a90ae32d27189ad9-080f-0515-e063-6394a90ae32d2024-11-17WarningsExact identifier
spl id: 27189ad9-0810-0515-e063-6394a90ae32d
spl set id: 27189ad9-080f-0515-e063-6394a90ae32d

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.